{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:34:11Z","timestamp":1791380051851,"version":"4.3.3"},"reference-count":33,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Purpose:\nwe aimed 1) to evaluate the risk factors associated to the benzodiazepines intake; 2) to assess the impact about the use of long acting injectables antipsychotics (LAIs); 3) to assess the risk in severe and affective disorders and 4) to identify the prescription patterns of use in mental health in a cohort of patients from Spain.\nMethods:\n735 outpatients from Mental Health were included. Demographic and clinical data were collected. In order to compare the use of benzodiazepines we calculated the daily dose equivalents (mg\/day) to diazepam as standard.\nResults:\nThe most commonly prescribed benzodiazepine was clonazepam (33%) and the mean daily dose of diazepam equivalents was 24.9 mg. It was higher in affective disorders (40.35 \u00b1 3.36) and lower in patients using LAIs antipsychotics (17.50 \u00b1 1.39; p = 0.001). Multivariate analysis showed that to be women (OR = 1.559, 95% CI = 1.059\u20132.295, p = 0.024), the use of drugs (OR = 1.671, 95% CI = 1.127\u20132.477, p = 0.011) and suffering any affective disorder (OR = 1.542, 95% CI = 1.355\u20131.826, p = 0.040) increased the risk of benzodiazepine intake. In contrast, the use of LAIs antipsychotics significantly reduced it versus oral antipsychotics (OR = 5.226, 95% CI = 3.185\u20138.575, p = 0.001).\nConclusions:\nbenzodiazepines are widely prescribed, mainly clonazepam followed by lorazepam and diazepam. Most of patients used at least one benzodiazepine and the mean daily intake was 25 mg diazepam equivalents. Therefore, benzodiazepines are extensively prescribed and used at higher doses than desirable. These, findings could be useful for clinicians and their practice.<\/jats:p>","DOI":"10.64719\/pb.4394","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"81-93","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of Risk Factors Associated to Prescription of Benzodiazepines and its Patterns in a Cohort of Patients from Mental Health: A Real World Study in Spain"],"prefix":"10.64719","volume":"51","author":[{"given":"Jorge","family":"Simal-Aguado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Pilar","family":"Campos-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Valdivia-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Galindo-Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Garc\u00eda-Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Wick JY. The history of benzodiazepines. Consult Pharm. 2013;28(9):538\u2013548. doi: 10.4140\/TCP.n.2013.538. doi:","DOI":"10.4140\/TCP.n.2013.538"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Schallek W, Horst WD, Schlosser W. Mechanisms of action of benzodiazepines. Adv Pharmacol Chemother. 1979;16:45\u201387. doi: 10.1016\/s1054-3589(08)60242-2. doi:","DOI":"10.1016\/s1054-3589(08)60242-2"},{"key":"ref3","unstructured":"Malcolm RJ. GABA systems, benzodiazepines, and substance dependence. J Clin Psychiatry. 2003;64(Suppl 3):36\u201340."},{"key":"ref4","unstructured":"Uzun S, Kozumplik O, Jakovljevi\u0107 M, Sedi\u0107 B. Side effects of treatment with benzodiazepines. Psychiatr Danub. 2010;22(1):90\u201393."},{"key":"ref5","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios\u2014Utilizaci\u00f3n de medicamentos ansiol\u00edticos e hipn\u00f3ticos en Espa\u00f1a durante el periodo 2000\u20132012. https:\/\/www.actasanitaria.com\/wpcontent\/uploads\/2014\/01\/ansioliticos_hipnoticos-2000\u20132012.pdf"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Paulose-Ram R, Jonas BS, Orwig D, Safran MA. Prescription psychotropic medication use among the U.S. adult population: results from the third national health and nutrition examination survey, 1988\u20131994. J Clin Epidemiol. 2004;57(3):309\u2013317. doi: 10.1016\/j.jclinepi.2003.05.001. doi:","DOI":"10.1016\/j.jclinepi.2003.05.001"},{"key":"ref7","unstructured":"McIntosh B, Clark M, Spry C. Benzodiazepines in Older Adults: a review of clinical effectiveness, cost-effectiveness, and guidelines. Ottawa (ON): canadian agency for drugs and technologies in health; 2011 [cited 2020 Aug 14]. (CADTH Rapid Response Reports). Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK174561\/"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Blanco C, Han B, Jones CM, Johnson K, Compton WM. Prevalence and Correlates of Benzodiazepine Use, Misuse, and Use Disorders Among Adults in the United States. J Clin Psychiatry. 2018;16:79(6):18m12174. doi: 10.4088\/JCP.18m12174. doi:","DOI":"10.4088\/JCP.18m12174"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Hollingworth SA, Siskind DJ. Anxiolytic, hypnotic and sedative medication use in Australia. Pharmacoepidemiol Drug Saf. 2010;19(3):280\u2013288.","DOI":"10.1002\/pds.1899"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Lagnaoui R, Depont F, Fourrier A, Abouelfath A, B\u00e9gaud B, Verdoux H, et al. Patterns and correlates of benzodiazepine use in the French general population. Eur J ClinPharmacol. 2004;60(7):523\u2013529.","DOI":"10.1007\/s00228-004-0808-2"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Demyttenaere K, Bonnewyn A, Bruffaerts R, De Girolamo G, Gasquet I, Kovess V, Haro JM, Alonso J. Clinical factors influencing the prescription of antidepressants and benzodiazepines: results from the European study of the epidemiology of mental disorders (ESEMeD) J Affect Disord. 2008;110(1\u20132):84\u201393. doi: 10.1016\/j.jad.2008.01.011. doi:","DOI":"10.1016\/j.jad.2008.01.011"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Pelayo H, F\u00e0brega-Ribera M, Garrido-Oca\u00f1a JM, Balcells-Oliver\u00f3 MM, Gual-Sol\u00e9 A. Risk perception in the ongoing prescription of benzodiazepines in mental health and primary care. Adicciones. 2014;26(2):184\u2013186.","DOI":"10.20882\/adicciones.21"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Panes A, Fourrier-R\u00e9glat A, Verdoux H, Tournier M. Use and misuse of benzodiazepines in patients with psychiatric disorders. Presse Med. 2018;47(10):886\u2013891. doi: 10.1016\/j.lpm.2018.10.003. doi:","DOI":"10.1016\/j.lpm.2018.10.003"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Clark RE, Xie H, Brunette MF. Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J Clin Psychiatry. 2004;65(2):151\u2013155. doi: 10.4088\/jcp.v65n0202. doi:","DOI":"10.4088\/jcp.v65n0202"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Valenstein M, Taylor KK, Austin K, Kales HC, McCarthy JF, Blow FC. Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatry. 2004;161(4):654\u2013661. doi: 10.1176\/appi.ajp.161.4.654. doi:","DOI":"10.1176\/appi.ajp.161.4.654"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Dong M, Zeng LN, Zhang Q, Yang SY, Chen LY, Najoan E, Kallivayalil RA et al. Prescription of antipsychotic and concomitant medications for adult Asian schizophrenia patients: findings of the 2016 research on asian psychotropic prescription patterns (REAP) survey. Asian J Psychiatr. 2019;45:74\u201380. doi: 10.1016\/j.ajp.2019.08.010. doi:","DOI":"10.1016\/j.ajp.2019.08.010"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Carmona JA, Simal-Aguado J, Campos-Navarro MP, Valdivia-Mu\u00f1oz F, Galindo-Tovar A. Long acting-injectables antipsychotics: analysis of prescription patterns and patient\u2019s characteristics in mental health from a Spanish real-world study. Clin Drug Inv. 2020;40(5):459\u2013468. doi: 10.1007\/s40261-020-00913-7. doi:","DOI":"10.1007\/s40261-020-00913-7"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u2013349. doi: 10.1016\/j.jclinepi.2007.11.008. doi.","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Andr\u00e9s JA, Garc\u00eda-Carmona JA. Clozapine, a controversial gold standard antipsychotic for the 21st century: switching to paliperidone palmitate 3-monthly improves the metabolic profile and lowers antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort. Schizophrenia Research. 2019;212:234\u2013236.","DOI":"10.1016\/j.schres.2019.08.001"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"B\u00e9nard-Laribi\u00e8re A, Noize P, Pambrun E, Bazin F, Verdoux H, Tournier M et al. Comorbidities and concurrent medications increasing the risk of adverse drug reactions: prevalence in French benzodiazepine users. Eur J Clin Pharmacol. 2016;72:869\u2013876.","DOI":"10.1007\/s00228-016-2044-y"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"van Eijk JTM, Bosma H, Jonkers CCM, Lamers F, Muijrers PEM. Prescribing Antidepressants and benzodiazepines in the Netherlands: is chronic physical illness involved. Depress Res Treat. 2010 https:\/\/doi.org\/10.1155\/2010\/10593 1.","DOI":"10.1155\/2010\/105931"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Kapil V, Green JL, Le Lait C, Wood DM, Dargan PI. Misuse of benzodiazepines and Z-drugs in the UK. Br J Psychiatr. 2014;205:407\u2013408.","DOI":"10.1192\/bjp.bp.114.149252"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Agarwal SA, Landon BE. Patterns in Outpatient Benzodiazepine Prescribing in the United States. JAMA Netw Open. 2019;2(1):e187399. doi: 10.1001\/jamanetworkopen.2018.7399. doi:","DOI":"10.1001\/jamanetworkopen.2018.7399"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry. 2015;72(2):136\u2013142. doi: 10.1001\/jamapsychiatry.2014.1763. doi:","DOI":"10.1001\/jamapsychiatry.2014.1763"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. Clin Ther. 2017;39(10):1972.e2\u20131985.e2.. doi: 10.1016\/j.clinthera.2017.08.008. doi:","DOI":"10.1016\/j.clinthera.2017.08.008"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Garcia-Carmona JA, Simal-Aguado J, Campos-Navarro P, Valdivia-Mu\u00f1oz F, Galindo-Tovar A. Evaluation of long-acting injectable antipsychotics with the corresponding oral formulation in a cohort of patients with schizophrenia: a real-world study in Spain. Int Clin Psychopharmacol. 2021;1(36):18\u201324. doi: 10.1097\/YIC.0000000000000339. doi:","DOI":"10.1097\/YIC.0000000000000339"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Mari\u0107 NP, Petrovi\u0107 SA, Jeroti\u0107 S, Risti\u0107 I, Savi\u0107 B, Zebi\u0107 M, Vukovi\u0107 V et al. Maintenance phase treatment of psychotic disorders in outpatients from Serbia\u2014focus on long-term benzodiazepine use. Int J Psychiatry Clin Pract. 2020;24(3):315\u2013321. doi: 10.1080\/13651501.2020.1767788.. doi:","DOI":"10.1080\/13651501.2020.1767788"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Comino-Naloto DC, Lopes CF, Barberato-Filho S, Cruz-Lopes L, Del Fiol FS, Bergamaschi C. Prescription of benzodiazepines for adults and older adults from a mental health clinic. Cien Saude Colet. 2016;21(4):1267\u20131276. doi: 10.1590\/1413-81232015214.10292015. doi:","DOI":"10.1590\/1413-81232015214.10292015"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Vicente-S\u00e1nchez MP, Mac\u00edas-Saint-Gerons D, de la Fuente-Honrubia C, Gonz\u00e1lez-Bermejo D, Montero-Corominas D, Catal\u00e1-L\u00f3pez F. Trends of use of anxiolytics and hypnotics in Spain from 2000 to 2011. Rev Esp Salud Publica. 2013;87(3):247\u2013255. doi: 10.4321\/S11357272013000300004. doi:","DOI":"10.4321\/S11357272013000300004"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Noia AS, Secoli SR, Duarte YAO, Lebr\u00e3o ML, Lieber NSR. Fatores associados ao uso de psicotr\u00f3picos em idosos no munic\u00edpio de S\u00e3o Paulo. Rev Esc Enferm USP. 2012;46:38\u201343.","DOI":"10.1590\/S0080-62342012000700006"},{"key":"ref31","unstructured":"Netto MUQ, Freitas O, Pereira LRL. Antidepressivos e benzodiazep\u00ednicos: estudo sobre o uso racional entre usu\u00e1rios do SUS em Ribeir\u00e3o Preto. Rev de Ci\u00eanc Farm B\u00e1sica e Aplic. 2012;33(1):77\u201381."},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Alvarenga JM, Loyola Filho AI, Firmo JO, Lima-Costa MF, Uchoa E. Prevalence and sociodemographic characteristics associated with benzodiazepines use among community dwelling older adults: the Bambu\u00ed health and aging study (BHAS) Braz J Psychiatry. 2008;30(1):7\u201311. doi: 10.1590\/s1516-44462006005000062. doi:","DOI":"10.1590\/s1516-44462006005000062"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Smith AJ, Tett SE. Improving the use of benzodiazepines\u2014is it possible? A non-systematic review of interventions tried in the last 20 years. BMC Health Serv Res. 2010;10:321. doi: 10.1186\/1472-6963-10-321. doi:","DOI":"10.1186\/1472-6963-10-321"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:28:36Z","timestamp":1791314916000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/evaluation-of-risk-factors-associated-to-prescription-of-benzodiazepines-and-its-patterns-in-a-cohort-of-patients-from-mental-health-a-real-world-study-in-spain\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4394","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}